Lenalidomide in the treatment of chronic lymphocytic leukemia

Expert Opinion on Investigational Drugs

Volumn 20, Issue 2, 2011, Pages 273-286

  Gentile, Massimo ^a   Recchia, Anna Grazia ^a   Vigna, Ernesto ^a   Mazzone, Carla ^a   Lucia, Eugenio ^a   Gigliotti, Vincenzo ^a   Bossio, Sabrina ^a   Madeo, Antonio ^a   Morabito, Lucio ^b   Servillo, Pasquale ^a   Franzese, Stefania ^a   Caruso, Nadia ^a   De Stefano, Laura ^a   Bisconte, Maria Grazia ^a   Gentile, Carlo ^a   Morabito, Fortunato ^a  

^a Azienda Ospedaliera di Cosenza   (Italy)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

chemotherapy; CLL; IMiDS compounds; lenalidomide

Indexed keywords

ALLOPURINOL; CD40 LIGAND; FC RECEPTOR; FLUDARABINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; IMMUNE DEFICIENCY; LYMPHOCYTOPENIA; NATURAL KILLER CELL; NEUTROPENIA; RASH; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; THALIDOMIDE; TUMOR MICROENVIRONMENT;

EID: 79951861397     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.546343     Document Type: Article

References (95)

1. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6. (Pubitemid 29295864)
2. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6.
3. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7. (Pubitemid 35217050)
4. Chronic Lymphocytic Leukemia. National Cancer Institute. SEER Stat Fact Sheets. Bethesda, MD: National Cancer Institute 2009. Available from: http://seer.cancer.gov/ statfacts/html/clyl.html. [Last accessed 13 December 2010].
5. Catovsky D, Foa R. The lymphoid leukaemias. Butterworths, London; 1990.
6. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94:448-54. (Pubitemid 29323859)
7. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855-64. (Pubitemid 8177910)
8. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
9. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7. (Pubitemid 29430399)
10. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002;116:142-5.
11. D'Arena G, Musto P, Cascavilla N, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42:109-14. (Pubitemid 32700928)
12. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262-9. (Pubitemid 36182494)
13. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181-6.
14. Gentile M, Mauro FR, Calabrese E, et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005;130:549-57. (Pubitemid 43899758)
15. Morabito F, Cutrona G, Gentile M, et al. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol 2009;146:44-53.
16. Durig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17:2426-34. (Pubitemid 38072581)
17. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923-30.
18. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54. (Pubitemid 29430400)
19. Hultdin M, Rosenquist R, Thunberg U, et al. Association between telomere length and VH gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 2003;88:593-8. (Pubitemid 36363370)
20. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262-4. (Pubitemid 34525519)
21. Gentile M, Cutrona G, Neri A, et al. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009;94:887-8.
22. Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969-75. (Pubitemid 46646223)
23. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-16. (Pubitemid 32064784)
24. Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-22. (Pubitemid 27143300)
25. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9.
26. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448-57. (Pubitemid 350232222)
27. Hallek M, Fingerle-Rowson G, Fink AM, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. ASH Annual Meeting Abstracts. Blood 2009;114:535.
28. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61. (Pubitemid 34534522)
29. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357-64. (Pubitemid 41503651)
30. Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759-65. (Pubitemid 38008843)
31. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196-203.
32. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404. (Pubitemid 46105932)
33. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-100. (Pubitemid 351213387)
34. Lenalidomide prescribing information. Summit, NJ: Celgene corporation,. http://www. revlimid.com/pdf/REVLIMID-PI.pdf [Last accesssed 13 December 2010].
35. Wu A, Scheffler MR. Multi-dose phamacokinetics and safety of CC-5013 in 15 multiple myeloma patients. J Clin Oncol 2004;22:141s.
36. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-22. (Pubitemid 38525287)
37. Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999;9:1625-30. (Pubitemid 29274209)
38. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002;100:1215-19. (Pubitemid 34864274)
39. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7.
40. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94:1266-73.
41. Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6. (Pubitemid 29295864)
42. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90. (Pubitemid 38268973)
43. Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-32. (Pubitemid 36618002)
44. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
45. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61. (Pubitemid 34921025)
46. Diederichsen ACP, Zeuthen J, Christensen PB, Kristensen T. Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J Cancer 1999;35:721-6. (Pubitemid 29258140)
47. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8. (Pubitemid 37248397)
48. Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1788-93. (Pubitemid 41486157)
49. Galustian C, Klaschka DC, Meyer B, et al. Lenalidomide (Revlimid(R), CC-5013) and ActimidTM (CC-4047) inhibit the function and expansion of T regulatory (Treg) cells in vitro: implications for anti-tumor activity in vivo. AACR Meeting Abstracts;. p. 1147.
50. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-45.
51. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37. (Pubitemid 351949771)
52. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001;28:602-6. (Pubitemid 33134419)
53. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16.
54. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650-7.
55. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms where by immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203.
56. Bartlett JB. Lenalidomide enhances tumor killing in vitro during ADCC mediated by trastuzumab, cetuximab, and rituximab. ASCO Meeting Abstracts. J Clin Oncol 2007;25:18S.
57. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:2005-10.
58. Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010;148:948-50.
59. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
60. James DF, Betty MR, Mosadeghi R, Kipps TJ. Lenalidomide abrogates the protective influence of nurse-like cells on primary chronic lymphocytic leukemia cells in vitro. ASH Annual Meeting Abstracts. Blood 2007;110:3116.
61. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC- 4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11:5984-92. (Pubitemid 41170330)
62. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36-45. (Pubitemid 350233246)
63. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005;7:E14-19. (Pubitemid 41554303)
64. Zhang L-H, Schafer PH, Muller G, et al. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-Hodgkin lymphoma cells are associated with increased SPARC expression. ASH Annual Meeting Abstracts. Blood 2008;112:2612.
65. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-67.
66. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67:746-55. (Pubitemid 46192215)
67. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30. (Pubitemid 34627223)
68. Chanan-Khan A. Pro-apoptotic effect of lenalidomide in patients with chronic lymphocytic leukemia is possibly mediated through interruption of phosphatidylinositol pathway. ASH Annual Meeting Abstracts. Blood 2006;108:2102.
69. Andritsos L, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-25.
70. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180-9.
71. Gaidarova S, Li JW, Corral LG, et al. Lenalidomide alone and in combination with rituximab enhances NK cell immune synapse formation in chronic lymphocytic leukemia (CLL) cells in vitro through activation of Rho and Rac1 GTPases. ASH Annual Meeting Abstracts. Blood 2009;114:3441.
72. Lapalombella R, Gowda A, Joshi T, et al. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009;144:848-55.
73. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase dependent pathway. Blood 2010;115:2619-29.
74. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-9. (Pubitemid 46623164)
75. Chanan-Khan A, Czuczman MS, Padmanabhan S, et al. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. ASH Annual Meeting Abstracts. Blood 2007;110:3108.
76. Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85-8.
77. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27:5404-9.
78. Moutouh-de Parseval LA, Weiss L, DeLap RJ, et al. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047. (Pubitemid 350220451)
79. Maddocks K, Lapalombella R, Blum KA, et al. Preliminary results of a Phase I study of lenalidomide in relapsed chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. Blood 2009;114:3446.
80. Wendtner CM, Mahadevan D, Stilgenbauer S, et al. Preliminary results of a phase 1/2, multi-center, open-label study (CLL-001) investigating a stepwise dose-escalation schedule of lenalidomide in relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. Blood 2008;112:2104.
81. Aue G, Soto S, Valdez J, et al. A phase II trial of pulse dosing lenalidomide: 3 weeks on 3 weeks off in previously treated chronic lymphocytic leukemia/ small lymphocytic lymphoma. ASH Annual Meeting Abstracts. Blood 2009;114:3427.
82. Chen CI, Paul H, Xu W, et al. Safety and efficacy of slow dose escalation of lenalidomide for frontline treatment in chronic lymphocytic leukemia (CLL) - results of a phase II study. Haematologica 2009;94:S93.
83. Badoux XC, Wierda WG, O'Brien SM, et al. Experience with lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. Haematologica 2009;94:S93.
84. Badoux XC, Reuben J, Lee B, et al. Lenalidomide therapy is associated with normalization of lymphocyte populations and increase in immunoglobulin levels in elderly patients with chronic lymphocytic leukemia. Haematologica 2009;94:S94.
85. Guegan JP, Quillet-Mary A, Laurent G, et al. Chronic lymphocytic leukemia/nurse-like cells interactions: release of soluble factor(s) that inhibit rituximab-dependent normal B cell depletion, and reversion by lenalidomide. Haematologica 2009;94:S28.
86. Brown JR, Abramson JS, Hochberg EP, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010;24:1972-5.
87. Brown JR, Abramson JS, Hochberg EP, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Haematologica 2009;94:S86.
88. Egle A, Steurer M, Melchardt T, et al. The REVLIRIT CLL5 AGMT study - a phase I/II trial combining fludarabine/ rituximab with escalating doses of lenalidomide followed by rituximab/ lenalidomide in untreated CLL: results of a planned interim analysis. ASH Annual Meeting Abstracts. Blood 2009;114:3453.
89. Ferrajoli A, Badoux XC, O'Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. Blood 2009;114:206.
90. Veliz M, Santana R, Lancet JE, et al. Phase II study of lenalidomide in combination with rituximab for patients with CD5+/CD20+ hematologic malignancies who relapse or progress after rituximab. Interim analysis. ASH Annual Meeting Abstracts. Blood 2009;114:2376.
91. Sher T, Miller K, Patel M, et al. Lenalidomide associated tumor flare reaction correlates with clinical response in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) [abstract 0928]. Haematologica 2009;94(Suppl 2):373.
92. Aue G, Njuguna N, Tian X, et al. Lenalidomide induced cytokine release syndrome in chronic lymphocytic leukemia (CLL): clinical and laboratory correlates of immune activation. ASH Annual Meeting Abstracts. Blood 2008;112:2099.
93. James D, Avery ED, Zhang L, et al. Lenalidomide administered for the initial treatment of CLL patients - in vivo modulation of the leukemia cell surface phenotype and association with tumor flare reaction (TFR). ASH Annual Meeting Abstracts. Blood 2009;114:3440.
94. Aue G, Lozier JN, Cullinane AM, et al. Increased incidence of thrombosis with lenalidomide in chronic lymphocytic leukemia: effect of lenalidomide on inflammation, endothelial cell damage and coagulation. ASH Annual Meeting Abstracts. Blood 2009;114:455.
95. Miller KC, Depaolo D, Padmanabhan S, et al. Prophylaxis of venous thromboembolism using weight-adjusted low-dose warfarin sodium in chronic lymphocytic leukemia (CLL) patients treated with immunomodulatory drugs (IMiDs). Leuk Lymphoma 2007;48(Suppl 1):131